Form 8-K - Current report:
SEC Accession No. 0001628280-25-005744
Filing Date
2025-02-14
Accepted
2025-02-14 16:25:51
Documents
15
Period of Report
2025-02-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20250214.htm   iXBRL 8-K 29312
2 EX-5.1 exhibit51stickerprosuppopi.htm EX-5.1 16837
6 GRAPHIC image_0.jpg GRAPHIC 38224
  Complete submission text file 0001628280-25-005744.txt   228184

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20250214.xsd EX-101.SCH 1894
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20250214_lab.xml EX-101.LAB 21900
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20250214_pre.xml EX-101.PRE 12611
17 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20250214_htm.xml XML 2828
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 25629441
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)